Novartis

Sales & Marketing

Four reasons pharma is sweeping the Super Bowl despite FDA f...

The FDA has signalled increased scrutiny of D2C pharma advertising. So why is pharma stepping up its advertising at Super Bowl LX?

News

Patent losses hit Novartis hard, but CEO has a plan

Novartis CEO Vas Narasimhan says the company is equipped to ride out "the largest patent expiry" in its history," but 2026 will still be tricky.

News

CMS's Medicare price negotiations start round three

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.

News

GSK reaches $2.2bn deal to buy food allergy biotech RAPT

GSK has made its first major acquisition under new CEO Luke Miels, buying RAPT Therapeutics and its food allergy prevention drug ozureprubart.

News

A globe atlas from above on a white surface

Novartis issues a life sciences warning in a 'G-Zero' world

Novartis claims life sciences lie at the centre of a shift in geopolitics and policies in regions like Europe, Japan, and Canada are "self-defeating."

R&D

JPM: The calm before the storm for radiotherapeutics

Radiotherapeutics have tremendous potential, but only a few therapies in market. But the technology is getting closer to its breakthrough moment.

Four reasons pharma is sweeping the Super Bowl despite FDA f...

Patent losses hit Novartis hard, but CEO has a plan

CMS's Medicare price negotiations start round three

GSK reaches $2.2bn deal to buy food allergy biotech RAPT

Novartis issues a life sciences warning in a 'G-Zero' world

JPM: The calm before the storm for radiotherapeutics

Lilly's 'triple G' retatrutide aces crucial obesity trial

Discover a new era of healthcare panel engagement: Grounded ...

Novartis

Editor's Picks